ArticleJournal of Alzheimer's disease reports
Pilot: Salivary lactoferrin as a potential preclinical Alzheimer's disease biomarker.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lactoferrin Levels in Cerebrospinal Fluid Exhibit Differential Associations with Alzheimer's Disease.Research square · 2026Article
- Lactoferrin levels in cerebrospinal fluid exhibits isoform-specific associations with Alzheimer's disease.medRxiv : the preprint server for health sciences · 2025Article
- Salivary lactoferrin levels in Down Syndrome: a case-control study.Brain, behavior, & immunity - health · 2025Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Alzheimer's disease (AD) research increasingly emphasizes accessible biomarkers for early detection. Lactoferrin, an iron-binding glycoprotein present in saliva, has been associated with AD pathology with mixed results. In this pilot study, saliva samples from 17 middle-to-older-aged Black and non-Hispanic White adults at risk for AD were measured. After adjusting for demographic variables, salivary lactoferrin (sLF) concentrations correlated significantly with Digit Span Memory Test scores (p = 0.013) and modestly with visuospatial performance (p = 0.194), with no racial differences observed. These preliminary results support further large-scale studies to assess sLF as a potential noninvasive biomarker for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.